Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple body scan predict IBD drug success?

NCT ID NCT07162701

Knowledge-focused Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study follows 48 adults with active Crohn's disease or ulcerative colitis who are starting biologic or JAK inhibitor therapy. Researchers use a quick, painless bioelectrical impedance scan to measure muscle mass and other body composition changes at the start, 24 weeks, and 52 weeks. The goal is to see if these changes can help predict how well the medication works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors predict which IBD treatments work best by monitoring simple body measurements like muscle mass.
What could go wrong
This is a small, early observational study, not a treatment trial. It may not lead to any changes in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with IBD (Crohn's disease and ulcerative colitis)

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any sex. * Age between 18 and 64 years. * Patients with a definitive diagnosis (\>3 months) of Crohn's disease or ulcerative colitis, according to European Crohn's and Colitis Organization criteria. * Moderate-to-severe disease luminal activity, with an indication for biologic or JAKi therapy for the induction of clinical remission. Exclusion Criteria: * Unclassified IBD. * History of intestinal resection for IBD, with the exception of ileocecal resection. * Short bowel syndrome. * Indication for medical treatment due to postsurgical recurrence. * Active perianal disease. * Indication for medical treatment due to intestinal stricture. * Previous participation in a clinical trial involving medication for IBD treatment. * Engaging in vigorous physical activity (\>6 Metabolic Equivalent of Task, METs) for more than 3 days per week. * Habitual alcohol consumption (\>1 standard drink unit/day). * Diabetes mellitus with inadequate glycemic control. * Chronic use of diuretics. * Chronic kidney disease on dialysis. * Presence of dependent edema and/or ascites. * Cardiac pacemaker bearers. * Pregnant or lactating women. * Inability to sign informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Body composition changes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colitis Crohn disease Malnutrition nutritional deficiency disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Body composition changes Malnutrition

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Unidad de Enfermedad Inflamatoria Intestinal

    RECRUITING

    Barcelona, 08025, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.